COMP <GO>
MDT vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Medtronic plc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MDT 4
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $97.11 (+2.46%) • MKT CAP: $124.22B
balance-sheet
3.08
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.00% | 70.20% | -5.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 29.00% | -21.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.4x | 33.3x | -15.90 | MDT | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 3.47% | +0.90 | MDT | /fcf-yield <GO> |
| Operating Margin | 17.80% | 24.60% | -6.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 8.40% | 8.60% | -0.20 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.93% | 2.27% | +0.66 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.08 | 5.33 | -2.25 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | MDT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.8 | 65.1 | -3.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.15 | -0.24 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $124.22B | $513.86B | -$389.64B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDT REV | ABBV REV | MDT GROSS % | ABBV GROSS % | MDT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.36B | $61.16B | 65.0% | 70.2% | $5.43B | $17.82B |
| FY 2024 | $33.54B | $56.33B | 65.3% | 70.0% | $5.18B | $17.83B |
| FY 2023 | $32.36B | $54.32B | — | — | $5.33B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDT // BETA 0.91
ABBV // BETA 1.15